$178.00 - $4,651.50

$178.00 - $4.00

Choose an Option...
  • 100 mg - $4,651.50
  • 50 mg - $3,286.00
  • 25 mg - $2,183.00
  • 5 mg - $652.00
  • 1 mg - $178.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

The OX101 monoclonal antibody reacts with CD47, an immunoglobulin superfamily protein that is ubiquitously expressed in various cells, including platelets and RBCs. CD47 is a heavily N-glycosylated multi-pass transmembrane protein with extracellular, helical, and cytoplasmic domains. This protein was originally identified as integrin-associated protein (IAP) and ovarian carcinoma antigen OA3, but subsequent studies identified CD47 as a "marker of self" on murine RBCs to prevent RBC clearance by splenic red pulp macrophages in the bloodstream by binding to SIRPα. CD47 binding partners include SIRPα, SIRPγ, TSP1, VEGFR-2, Serpin A1, Integrins (αv²3, αM²2, α4²1, etc.), BNIP3, CDC42, PI3K, Src, and others. CD47 functions as a cognate receptor for TSP1, and the CD47-TSP1 pathway plays a significant role in the pathophysiology of vascular disease, wherein CD47-TSP1 signaling acts via adenylate cyclase activation, stimulation of apoptosis, and regulation of nitric oxide and Nox1. Besides various normal cells, CD47 is also expressed in various tumor cells, and studies have established CD47 as a biomarker of malignant tumors. By blocking the CD47-SIRPα interaction in cancer cells, scientists have found that the CD47-SIRPα axis acts as a tumor phagocytosis checkpoint, telling macrophages "don't eat me”. This signaling is thought to be a way for many tumor cells to escape the immune system. The CD47-SIRPα signaling axis controls immunity through the Hedgehog/SMO/Gli1 signaling pathway, and the blockade of CD47 or targeting its binding protein SIRPα is known to upregulate both innate and adaptive anti-tumor immune responses. Targeting CD47 and its regulators is emerging as a promising therapeutic approach in cancer immunotherapy, and preclinical experiments have indicated CD47 blockade to demonstrate potent anti-cancer activity in several hematologic cancers.

Specifications

Isotype Mouse IgG1, κ
Recommended Isotype Control(s) InVivoMAb mouse IgG1 isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Rat thymocytes
Reported Applications in vivo blockade of CD47
in vitro blockade of CD47
Functional assays
Immunohistochemistry (frozen)
Flow cytometry
Immunoprecipitation
Western blot
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤1EU/mg (≤0.001EU/μg)
Determined by LAL assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein G
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Application References

  • Western Blot in vitro blockade of CD47
    Vernon-Wilson EF, Kee WJ, Willis AC, Barclay AN, Simmons DL, Brown MH (2000). "CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1" Eur J Immunol 30(8):2130-7.

    The rat OX41 antigen is a cell surface protein containing three immunoglobulin superfamily domains and intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM). It is a homologue of the human signal-regulatory protein (SIRP) also known as SHPS-1, BIT or MFR. Cell activation-induced phosphorylation of the intracellular ITIM motifs induces association with the tyrosine phosphatases SHP-1 and SHP-2. To identify the physiological OX41 ligand, recombinant OX41-CD4d3+4 fusion protein was coupled to fluorescent beads to produce a multivalent cell binding reagent. The OX41-CD4d3+4 beads bound to thymocytes and concanavalin A-stimulated splenocytes. This interaction was blocked by the monoclonal antibody (mAb) OX101. Affinity chromatography with OX101 mAb and peptide sequencing revealed the rat SIRP ligand to be CD47 (integrin-associated protein). A direct interaction between human SIRP and human CD47 was demonstrated using purified recombinant proteins and surface plasmon resonance ruling out the involvement of other proteins known to be associated with CD47. The affinity of the SIRP/CD47 interaction was K(d) approximately 8 microM at 37 degrees C with a k(off )>/=2.1 s(-1). The membrane-distal SIRP V-like domain was sufficient for binding to CD47.

  • Immunohistochemistry (frozen) Flow Cytometry Functional Assays in vitro blockade of CD47
    de Vries HE, Hendriks JJ, Honing H, De Lavalette CR, van der Pol SM, Hooijberg E, Dijkstra CD, van den Berg TK (2002). "Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium" J

    Monocyte infiltration into inflamed tissue requires their initial arrest onto the endothelial cells (ECs), followed by firm adhesion and subsequent transmigration. Although several pairs of adhesion molecules have been shown to play a role in the initial adhesion of monocytes to ECs, the mechanism of transendothelial migration is poorly defined. In this study, we have investigated the role of signal-regulatory protein (SIRP)alpha-CD47 interactions in monocyte transmigration across brain ECs. CD47 expression was observed in vivo on cerebral endothelium of both control animals and animals suffering from experimental allergic encephalomyelitis. To investigate whether SIRPalpha-CD47 interactions are instrumental in the trafficking of monocytes across cerebral EC monolayers, in vitro assays were conducted in which the migration of monocytes, but not adhesion, was found to be effectively diminished by blocking SIRPalpha and CD47 on monocytes and ECs, respectively. In this process, SIRPalpha was found to interact solely with its counterligand CD47 on ECs. Overexpression of the CD47 molecule on brain ECs significantly enhanced monocytic transmigration, but did not affect adhesion. SIRPalpha-CD47-mediated transendothelial migration involved Gi protein activity, a known signaling component of CD47. Finally, cross-linking of CD47 on brain ECs induced cytoskeletal reorganization of the endothelium, a process that was Gi protein independent. These data provide the first evidence that the interaction of CD47 with its monocytic counterligand SIRPalpha is of importance in the final step of monocyte trafficking into the brain, a critical event in the development of neuroinflammatory diseases.

  • in vitro blockade of CD47
    Sick E, Niederhoffer N, Takeda K, Landry Y, Gies JP (2009). "Activation of CD47 receptors causes histamine secretion from mast cells" Cell Mol Life Sci 66(7):1271-82.

    Mast cells play pivotal roles in allergic and inflammatory processes via distinct activation pathways. Mucosal and serosal mast cells are activated by the IgE/FcepsilonRI pathway, while only serosal mast cells are activated by basic secretagogues. We show that CD47 receptors are expressed on rat peritoneal mast cells. 4N1K, a peptide agonist of CD47, rapidly caused exocytosis. Such exocytosis required increased intracellular calcium and was inhibited by pertussis toxin and an antibody against the betagamma dimer of a G(i) protein. Cooperation with integrins and glycosylphosphatidylinositol-anchored proteins was necessary, since anti-integrin antibodies and pretreatment with phosphatidylinositol-phospholipase C reduced exocytosis. Depletion of membrane cholesterol inhibited exocytosis and decreased CD47 in lipid rafts, consistent with a CD47/integrin/G(i) protein complex being located in rafts. An anti-CD47 antibody inhibited exocytosis induced by 4N1K and by mastoparan and spermine, suggesting that basic secretagogues might target CD47. We propose that 4N1K-stimulated mast cell exocytosis involves a CD47/integrin/G(i) protein complex.

  • in vitro blockade of CD47
    Alblas J, Honing H, de Lavalette CR, Brown MH, Dijkstra CD, van den Berg TK (2005). "Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-depen

    Signal regulatory protein alpha (SIRPalpha) is a glycoprotein receptor that recruits and signals via the tyrosine phosphatases SHP-1 and SHP-2. In macrophages SIRPalpha can negatively regulate the phagocytosis of host cells and the production of tumor necrosis factor alpha. Here we provide evidence that SIRPalpha can also stimulate macrophage activities, in particular the production of nitric oxide (NO) and reactive oxygen species. Ligation of SIRPalpha by antibodies or soluble CD47 triggers inducible nitric oxide synthase expression and production of NO. This was not caused by blocking negative-regulatory SIRPalpha-CD47 interactions. SIRPalpha-induced NO production was prevented by inhibition of the tyrosine kinase JAK2. JAK2 was found to associate with SIRPalpha in macrophages, particularly after SIRPalpha ligation, and SIRPalpha stimulation resulted in JAK2 and STAT1 tyrosine phosphorylation. Furthermore, SIRPalpha-induced NO production required the generation of hydrogen peroxide (H(2)O(2)) by a NADPH oxidase (NOX) and the phosphatidylinositol 3-kinase (PI3-K)-dependent activation of Rac1, an intrinsic NOX component. Finally, SIRPalpha ligation promoted SHP-1 and SHP-2 recruitment, which was both JAK2 and PI3-K dependent. These findings demonstrate that SIRPalpha ligation induces macrophage NO production through the cooperative action of JAK/STAT and PI3-K/Rac1/NOX/H(2)O(2) signaling pathways. Therefore, we propose that SIRPalpha is able to function as an activating receptor.

Product FAQs

Related Products

  1. Catalog #BP0283
    InVivoPlus anti-mouse/human/rat CD47 (IAP) Read more
  2. Catalog #BE0283
    InVivoMAb anti-mouse/human/rat CD47 (IAP) Read more
  3. Catalog #BE0270
    InVivoMAb anti-mouse CD47 (IAP) Read more
  4. Catalog #BE0019-1
    InVivoMAb anti-human CD47 Read more